New drug cocktail aims to shrink stomach tumors before surgery

NCT ID NCT07581574

Not yet recruiting Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a combination of two drugs—trastuzumab rezetecan and retlirafusp alfa—in 12 people with HER2-positive stomach or gastroesophageal junction cancer. The treatment is given before surgery to see if it can safely shrink tumors. The main focus is on safety and finding the right dose, with secondary goals like how many patients have no cancer left after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trastuzumab rezetecan (antibody-drug conjugate) and retlirafusp alfa (immunotherapy drug)
What this could lead to: If this works, it could point toward a more effective pre-surgery treatment for HER2-positive gastric cancer, potentially improving tumor shrinkage and long-term outcomes.
What could go wrong: This is a very early, small phase 1b trial with only 12 participants and no control group. The main goal is safety, so it's too soon to know if the combo truly helps. Side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

First Affiliated Hospital of Nanjing Medical Unviersity

Nanjing, Jiangsu, 210000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.